HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Atazanavir: in pediatric patients with HIV-1 infection.

Abstract
Atazanavir is a selective and potent inhibitor of the HIV-1 protease. The drug is administered in combination with low-dose ritonavir, to boost atazanavir pharmacokinetics (i.e. ritonavir-boosted atazanavir), and other antiretroviral agents. The efficacy of once-daily ritonavir-boosted atazanavir plus background therapy (BT) in establishing virologic suppression in treatment-naive pediatric patients (aged 6 to <18 years) infected with HIV-1 was demonstrated in an ongoing, open-label, multicenter, phase I/II trial (PACTG 1020A). HIV-1 RNA levels of <50 or <400 copies/mL were achieved by the majority of patients (>70%) after 24 weeks' therapy, with these benefits maintained at week 48. Some treatment-experienced pediatric patients (aged 6 to <18 years) also achieved HIV-1 RNA levels of <50 or <400 copies/mL in the PACTG 1020A trial after 24 (≤45% of patients) and 48 (≤32%) weeks of treatment with ritonavir-boosted atazanavir plus BT, although the benefits of the regimen in this patient population appeared to be limited by as few as one or two protease inhibitor resistance mutations. Treatment-experienced pediatric patients (aged 10-19 years) infected with HIV-1 had mixed success in establishing/maintaining virologic suppression when they were switched from their current antiretroviral treatment regimen to once-daily ritonavir-boosted atazanavir plus BT in a small, single-center, observational study. However, some patients may have received atazanavir at a suboptimal dosage or had suboptimal susceptibility to BT agents. In the PACTG 1020A trial, use of atazanavir (with or without ritonavir) in pediatric patients aged 6 to <18 years was associated with a similar safety profile to that reported in adults.
AuthorsEmma D Deeks
JournalPaediatric drugs (Paediatr Drugs) Vol. 14 Issue 2 Pg. 131-41 (Apr 01 2012) ISSN: 1179-2019 [Electronic] Switzerland
PMID22292486 (Publication Type: Journal Article, Review)
Chemical References
  • HIV Protease Inhibitors
  • Oligopeptides
  • Pyridines
  • Atazanavir Sulfate
  • Ritonavir
Topics
  • Acquired Immunodeficiency Syndrome (drug therapy)
  • Adolescent
  • Area Under Curve
  • Atazanavir Sulfate
  • Child
  • Clinical Trials as Topic
  • Drug Administration Schedule
  • Drug Interactions
  • Drug Resistance, Viral
  • Drug Therapy, Combination
  • HIV Protease Inhibitors (administration & dosage, adverse effects, blood, pharmacokinetics)
  • HIV-1 (drug effects)
  • Humans
  • Multicenter Studies as Topic
  • Oligopeptides (administration & dosage, adverse effects, blood, pharmacokinetics)
  • Pyridines (administration & dosage, adverse effects, blood, pharmacokinetics)
  • Ritonavir (administration & dosage, adverse effects)
  • Treatment Outcome
  • Viral Load (drug effects)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: